WORCESTER, Mass., Nov. 2, 2009 (GLOBE NEWSWIRE) -- Bill Abajian, Senior Executive Advisor for Global Licensing and Business Development for Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), is featured on the Doggie Chronicles Radio Program -- "a show all about dogs and the people who love them." The audio segment is available to listen online at http://tr.im/GRSpets and as a podcast via iTunes.
With program hosts Lisa Gorman and Scott Sheppard, Abajian discussed hypoglycemia in dogs and cats and how Generex's proprietary Glucose RapidSpray(TM), marketed for humans and their pets, is a convenient way to maintain blood glucose levels throughout the day.
There are more than 72 million pet dogs and nearly 82 million pet cats in the United States. About one in 500 of these pets eventually develops diabetes mellitus such that additional dietary glucose may be desirable. Glucose RapidSpray(TM) is designed to provide this additional dietary glucose.
"Some dogs are especially at risk of low blood sugar events and a seizure that goes along with it," said Abajian. "During the process of developing a product for humans, Generex has invented a glucose spray for the first signs of low blood sugar. It's administered through the pet's mouth, gets into the bloodstream within three minutes, and raises its blood sugar."
Glucose RapidSpray(TM) is a scientifically formulated and easy-to-use liquid glucose spray that is absorbed by the inner lining of the mouth without any chewing or swallowing. Other potential uses for Glucose RapidSpray(TM) for pets include newborn dogs and cats, toy breeds, hunting dogs, show dogs, pre-and-post operative care, aging pets, and pets with low appetites.
"This exciting product provides a much more user-friendly option for pet owners to react effectively to their pets' needs and an alternative to administering large pills and other tedious methods," continued Abajian. "Glucose RapidSpray(TM) has been very well received in the veterinary community, and is available in the U.S. and Canada through local veterinarians, retailers and online at www.glucoserapidspraypets.com."
Earlier this year Generex entered into an agreement with Butler Animal Health Supply LLC, the nation's leading distributor of companion animal health supplies to veterinarians, to distribute Glucose RapidSpray(TM) (www.glucoserapidspraypets.com) in the United States. McCarthy and Sons Service, a leading Canadian sales firm to veterinarians and veterinarian hospitals in the animal health industry in Canada, distributes the product there.
The global animal health market was worth $17.4 billion in 2005 with a forecast annual compound growth rate of 4.5 percent to $21.7 billion in 2010. The United States accounts for 36 percent of the global market. The Pet Product Manufacturers Association estimates that U.S. consumers spent in excess of $40 billion on their pets in 2007.
Marketreserach.com states that during the ten-year period from 1995-2005, pet spending tripled for households with incomes above $70,000, and spending on convenience products for pets grew 20 percent from 2005 to 2006 alone.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.